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Tissue kallikrein and factor Xa were found to activate tissue plasminogen activator (t-PA) at a rate compa- 
rable with that of plasmin. During the activation reaction, the single-chain molecule was converted into 
a two-chain form. A slight t-PA activating activity was also found in plasma kallikrein. Other activated 
coagulation factors, factor XIIa, factor XIa, factor IXa, factor VIIa, thrombin and activated protein C had 
no effect on t-PA activation. t-PA was also activated by a tissue kallikrein-like enzyme that was isolated 
from the culture medium of melanoma cells. These results indicate that tissue kallikrein and factor Xa may 
participate in the extrinsic pathway of human fibrinolysis. 
Fibrinolysis t-PA Tissue kallikrein Coagulation factor 
1. INTRODUCTION 
Tissue plasminogen activator (t-PA) is widely 
distributed in tissues [l] and plays an important 
role in fibrinolysis, converting plasminogen to 
plasmin. Plasmin in turn is responsible for fibrin 
clot dissolution. t-PA is released into the cir- 
culating blood from the vascular endothelial cells 
[2], although at an extremely low concentration 
[31. 
The incorporation of diisopropylfluorophos- 
phate into an active form of t-PA [4,5] and the 
primary structure of t-PA predicted from its c- 
DNA sequence [6] revealed that this protein is a 
typical serine protease. t-PA isolated from tissues 
[5,7] or cell culture [4] is an active enzyme that is 
Abbreviations: t-PA, tissue plasminogen activator; -p- 
NA, -p-nitro-anilide; SBTI, soybean trypsin inhibitor; 
LBTI, lima bean trypsin inhibitor; HMW-kininogen, 
high molecular mass kininogen; TBS, 50 mM Tris-HCl 
buffer (pH 7.5) containing 0.15 M NaCl. (Here, t-PA 
and vascular plasminogen activator are considered to be 
identical proteins. Thus, both proteins are referred to as 
t-PA.) 
* To whom correspondence should be addressed 
composed of two polypeptide chains linked by a 
disulfide bond. t-PA isolated from the blood vessel 
perfusate is present in a zymogen form as a single 
polypeptide chain [8]. t-PA, however, was readily 
converted into the two-chain form by a protease 
present in the perfusate and this conversion was 
prevented by the addition of protease inhibitors 
PI. 
These findings suggest hat an enzyme(s) present 
in tissue may be responsible for the conversion of 
the zymogen of t-PA into the active form. Further- 
more, there may be a plasma enzyme(s) that ac- 
tivates t-PA following its release into blood. Thus 
far, plasmin and trypsin have been shown to ac- 
tivate the zymogen of t-PA in vitro. In the presence 
of plasmin, a single internal peptide bond in t-PA 
is cleaved to form the two-chain molecule [7,10]. 
Plasmin, however, must first be generated before 
it can participate in this reaction. This suggests 
that some other plasma serine protease such as a 
coagulation factor may trigger the activation of t- 
PA. 
We describe the results of the activation of t-PA 
by both tissue kallikrein and several blood coagu- 
lation enzymes. A part of this study was presented 
in [ll]. 
Published by Elsevier Science Publishers B. K 
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2. MATERIALS AND METHODS 
Serum-free conditioned medium of melanoma 
cells (Bowes) was kindly provided by Charles Hart 
of ZymoGenetics, Seattle, WA. t-PA was purified 
in the presence of 20 KIU units/ml of aprotinin by 
the same method as described in [4]. The final 
preparation of t-PA was concentrated by dialysis 
first against 40% polyethylene glycol-20080 and 
subsequently against 40 mM Tris-HCl buffer (pH 
7.5) containing 1 M NaCl and 0.01% Tween-80. 
Homogeneous human coagulation factors, factor 
XIIa [12], factor XI [13], prekallikrein [14], factor 
VIIa [15], thrombin 1161, activated protein C [17], 
antithrombin-III [18] and factor X [19] were 
purified according to methods published from this 
laboratory. Factor XI and prekallikrein were ac- 
tivated by factor XIIa. Factor X was activated by 
the factor X-activating enzyme from Russell’s 
viper venom. Factor IXa [20], HMW-kininogen 
[21], tissue factor [22] were prepared by published 
methods. Porcine pancreatic kallikrein (200 units/ 
mg) was purchased from Calbiochem and further 
purified at 4°C as follows: 5 mg of tissue kallikrein 
was dissolved in 2 ml of TBS and passed through 
a LBTI-Sepharose column (1.5 x 6 cm) to remove 
any contaminating trypsin. The unadsorbed frac- 
tion was then applied to an aprotinin-Sepharose 
column (1.5 x 8 cm) equilibrated with TBS. Pro- 
tein was eluted with 0.1 M Tris-HCl (pH 7.5) con- 
taining 1 M NaCl and 0.5 M benzamidine. Follow- 
ing concentration of the eluate, the sample was ap- 
plied to a Sephadex G-150 column (0.9 x 50 cm) 
equilibrated with TBS. The active fractions, as 
determined by assay with Val-Leu-Arg-p-NA, were 
pooled and concentrated to 0.5 ml by a Micro- 
ProDiCon concentrator. Monospecific antisera 
against human factor X was raised in rabbits by 
the standard procedure [23 1. Affinity-purified 
anti-factor X was prepared as described 1241. 
D-Val-Gly-Arg-p-NA (S-2322) was obtained 
through the courtesy of Dr P. Friberger, Kabi, 
Molndal, Sweden. D-Val-Leu-Arg-p-NA (S-2266) 
was purchased from Helena Lab. p-Aminobenza- 
midine-Sepharose with a spacer of e-aminocaproic 
acid [ 1 l] were prepared by the published methods. 
SBTI (70 mg), LBTI (100 mg) and aprotinin (25 
mg) were bound to 3 g activated CH-Sepharose ac- 
cording to Pharmacia’s instruction. 
The activation of t-PA was determined by 
measuring the amidolytic activity of the two-chain 
form of t-PA with Val-Gly-Arg-p-NA. Single- 
chain t-PA (3 ,ug) in 15 ~1 of 50 mM Tris-HCl (pH 
7.5) containing 1 mM NaCl and 0.01% Tween-80 
was added to a catalytic amount of enzyme in 85 
pl of 50 mM Tris-HCl, pH 7.5. At appropriate 
periods of incubation at 37’C, 10~1 of aprotinin 
(at a final concentration of 5 pg/ml) and 800~1 of 
1 mM Val-Gly-Arg-p-NA were added and in- 
cubated at 37°C. The initial rate of p-nitroaniline 
release was determined and the enzyme activity 
was expressed as AAm5 ,/Min per pg of protein. 
Aliquots (35 ~1) were also withdrawn at the same 
times and mixed with 3 /tl of 1 M Tris-HCl (pH 
6.9) containing 2% SDS and 5% bromophenol 
blue, heated at 80°C for 20 min with or without 
2% 2-mercaptoethanol and subjected to SDS-slab 
electrophoresis. SDS-slab gel electrophoresis was 
performed in 10% polyacrylamide gel as described 
by Laemmli. Protein bands were visualized by 
silver staining. t-PA was iodinated by the method 
of [25] using Iodo-Beads (Pierce). Protein concen- 
tration of t-PA was determined by the method of 
Lowry and the published ,?&F pm values [12-211 
were used for determination of the other protein 
concentrations. 
3. RESULTS 
3.1. Activation of t-PA by t&we kallikrein 
The two-chain of t-PA is the principal form of 
the protein purified from the culture medium of 
melanoma cells. The addition of aprotinin to the 
culture medium increased the amount of the single- 
chain t-PA with a concomitant decrease of the 
two-chain t-PA [4]. This suggests that plasmin, 
tissue kallikrein or some other trypsin-like enzymes 
sensitive to aprotinin, may cause the formation of 
the two-chain molecule by limited proteolysis. 
Accordingly~ a purified preparation of porcine 
pancreatic kallikrein (tissue kallikrein) was ex- 
amined for its ability to activate t-PA. The single- 
chain of t-PA was incubated with tissue kallikrein 
at a substrate/enzyme weight ratio of 50/l. The 
amidolytic activity of t-PA increased gradually and 
reached a maximum in approx. 2 h (fig. 1A). At 
this time, a lo-fold increase of enzyme activity was 
observed over the zero-time control. The activa- 
tion by tissue kallikrein was completely inhibited 
413 
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Reaction lime (hr) Reaction Time (hr) 
Fig. 1. The time curve for the activation of t-PA >by tissue kallikrein (A) and factor Xa (B). (A) The single-chain of 
t-PA (3 pg) was incubated with 26 ng of tissue kallikrein a d arnidolytic activity was measured as described in section 
2. The complete reaction, 0; with 5 #g/ml aprotinin, l; with 5 /rg/ml SBTI, 0 ; with 5 @g/ml LBTI, m ; t-PA alone, 
A . (B) t-PA (3 /cg) was incubated with 60 ng of factor Xa in the same condition as described in (A). The complete 
reaction, 0; the reaction with 5 rg/ml antithrombin-IWheparin complex, l; with 5 pg/ml SBTI or LBTI, 0 ; with 5 
pg/ml aprotinin, n ; with 2 mM CaC12, A . 
by aprotinin, but not by SBTI or LBTI. These data 
are consistent with the sensitivity of tissue kalli- 
krein to these 3 protein inhibitors [26]. 
The molecular changes of t-PA associated with 
its activation were examined by SDS-slab gel elec- 
trophoresis. In reduced gels, the starting material 
showed one major doublet corresponding to Mr 
64008 along with two minor bands of M, 36 000 
and 34000 (fig. 2A). The two minor bands reflect 
the presence of the two-chain form of t-PA in the 
starting material. During the activation by tissue 
kallikrein, the intensity of the M, 64000 band 
decreased, while the bands of M, 36 000 and 34 000 
increased. After 2 h, the single-chain molecule was 
completely converted to the two-chain form (fig. 
2A). To ascertain the proportional relationship 
between the formation of the two-chain form and 
the generation of amidolytic activity, following ex- 
periments were performed. The radio-labelled 
single-chain t-PA was activated under the same 
condition as in fig. 1. Amidolytic activities were 
measured with the samples taken at the various 
times and aliquots from the same samples were 
also run on SDS- gels. The gels were sliced and 
radioactivity of the bands corresponding to lK 
414 
64000 and 34 000- 36000 were measured. The 
generation of enzyme activities were proportional 
to the amount of two-chain formed throughout the 
activation (fig. 3). 
In non-reduced gels, the doublet of M, 64 000 re- 
mained constant throughout the reaction, in- 
dicating that the two-chains were linked by a 
disulfide bond(s). Additional cleavage of t-PA was 
not observed, even after prolonged incubation for 
20 h. The effect of SBTI, LBTI, antithrombin 
IIVheparin complex and hirudin on the cleavage 
of the t-PA molecule by tissue kallikrein were also 
examined by SDS-slab gel electrophoresis. Com- 
plete inhibition of the cleavage of t-PA was ob- 
served in the presence of aprotinin, while the other 
inhibitors had no effect on the activation reaction 
(not shown). 
3.2. Isolation of tissue kallikrein-like protease 
from the culture medium of melanoma cells 
and its action on t-PA 
One liter of the serum-free culture medium 
(without aprotinin) was dialyzed extensively over- 
night at 4°C against 50 mM Tris-HCl buffer (pH 
7.5) containing 0.01% Tween-80. The dialyzed 
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Fig. 2. SDS-slab gel electrophoresis of the activation products of t-PA by tissue kallikrein and factor Xa. The same 
reaction mixtures containing 1 /rg of t-PA as described in the legend of fig.1 were subjected to gel electrophoresis. 
Numbers at the bottom of the gels represent the reaction time in hours. 
sample was clarified by centrifugation and applied 
to three different specific affinity columns in- 
cluding lysine-Sepharose, SBTI-Sepharose and 
aprotinin-Sepharose. Enzyme activity in the 
dialyzed sample failed to bind either lysine- 
Sepharose or SBTI-Sepharose. This suggests that 
the enzyme present in the melanoma culture 
medium is neither plasmin nor trypsin. The culture 
medium was then applied to an aprotinin- 
Sepharose column (2.0 x 5 cm) previously equili- 
brated with TBS. The column was eluted with 0.5 
M benzamidine in TBS, dialyzed and concentrated 
against TBS to a final vol. of 0.5 ml. As shown in 
table 1, amidolytic activity was detected in this 
fraction when it was assayed with D-Val-Leu-Arg- 
I?-NA. Furthermore, this activity was very sensitive 
to aprotinin, but not to SBTI or LBTI. This in- 
hibitor sensitivity is identical with that of porcine 
pancreatic kallikrein (see fig. 1A). 
Since a limited amount of the tissue kallikrein- 
like activity was obtained, the activation of t-PA 
by this enzyme was examined only after 20 h in- 
cubation. The single-chain of t-PA was incubated 
with 20~1 of the sample of tissue kallikrein-like en- 
zyme that was equivalent o approximately 10% of 
the amidolytic activity of porcine kallikrein used in 
the experiment shown in fig. 1A. The generation of 
amidolytic activity of t-PA was observed. About 
70% of the single-chain t-PA was converted into 
the two-chain form. This reaction was completely 
inhibited by aprotinin, but not by LBTI (table 1). 
These results indicate that the melanoma cells 
secrete tissue kallikrein or a tissue kallikrein-like 
protease into the culture medium, and this enzyme 
is responsible for the formation of the two-chain 
form of t-PA. 
3.3. Activation of t-PA activated coagulation 
factors 
Various activated coagulation factors were in- 
cubated with single-chain t-PA at an enzyme to 
substrate weight ratio of 1: 50. The contact fac- 
tors, factor XIIa, factor XIa and kallikrein, were 
studied in the presence or absence of cofactors, 
such as HMW-kininogen and kaolin. Effect of 
phospholipid, CaClz and tissue factor were also ex- 
amined with the vitamin Kdependent proteases, 
such as factor VIIa, factor IXa, factor Xa, and ac- 
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Two-chain t-PA (%I 
tivated protein C. These cofactors are essential for 
maximum activity of these enzymes in the coagula- 
tion cascade [27]. 
Table 2 shows the results of the activation of 
t-PA by several coagulation factors and tissue en- 
zymes. Factor Xa was found to readily activate 
Table 1 
Enzyme activity of tissue kallikrein-like protease from 
the culture medium of melanoma cells 
Reactions Enzyme activity 
Reaction Reaction Reaction 
without with with 
inhibitor aprotinin LBTI 
Amidolytic act.a 0.440 0.071 0.441 
Activating actb 0.100 0.018 0.093 
for T-PA 
* Tissue kallikreln-like protease isolated from the 
culture medium of melanoma cells, 20 ~1, was in- 
cubated for 2 h with 200~1 of 1 mM D-Val-Leu-Arg-p- 
NA and 80 pl of TBS in the presence or absence of 5 
pg/ml of the inhibitor. The absorbance was measured 
after the addition of 700~1 of 7% acetic acid. Enzyme 
activity was expressed as A&s ,,,,,/20 h per 20 ~1 
b 3 pg t-PA was incubated with 20~1 of tissue kallikrein- 
like protease for 20 h in the presence or absence of 5 
pg/ml of the inhibitors and t-PA was assayed in the 
same conditions as described in section 2. Enzyme ac- 
tivity was expressed as A.4405 ,/min per pg of t-PA 
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Fig. 3. The proportional relationship between the forma- 
tion of the two-chain t-PA and the generation of its 
amidolytic activity. Single-chain t-PA was activated 
under essentially the same condition as described in fig. 1 
except that 0.15 cg of t2’I-t-PA (3.6 x 16 cpm/pg) was 
added to the reaction mixture. At 0, l/4, l/2, 1, 2 and 
4 h, allquots were taken and amldoIytic activities were 
measured as described in section 2. Other aliquots were 
run on the reduced 7.5% SDS-gels. The gels were sliced 
after staining and radioactivity of the bands correspond- 
ing to && 64000 and 34000-36CIOO were measured. The 
enzyme activity generated and the amount of two-chain 
formed were expressed as percent of the maximum (4 h). 
Activation by tissue kallikrein, 0 and by factor Xa, l . 
t-PA and this reaction leveled off at about 2 h in- 
cubation (fig. 1B). The activation of t-PA by fac- 
tor Xa was not observed in the presence of anti- 
thrombin III/heparin complex. LBTI or aprotinin 
Table 2 
Activation of t-PA by tissue and plasma enzymes 
Activators Amidolytic activity of t-PA 
(AA405 &min per /cg 
of t-PA) 
30-min 2-h incubation 
incubation 
Tissue enzymes 
Pancreatic kallikrein 
Bovine trypsin 
0.050 0.108 
0.099 0.122 
Human plasma enzymes 
Kallikrein 
Factor XIIa 
Factor XIa 
Factor IXa 
F&tor VIIa 
Factor Xa 
a-Thrombin 
Activated protein C 
0.040 
0.024 
0.014 
0.012 
0.013 
0.071 0.118 
0.012 
0.014 
Plasmin 0.095 0.122 
Without activator 0.012 0.012 
The single-chain of t-PA (3 /rg) was activated by the en- 
zymes at an enzyme/substrate weight ratio of l/50 under 
the same conditions as described in the legend of fig. 1B. 
t-PA activity was assayed with D-Val-Gly-Arg-p-NA as 
described in section 2. -, not determined. 
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had no detectable ffect on the activation reaction, 
while SBTI had a slight inhibitory effect. During 
the activation of t-PA by factor Xa, single-chain 
t-PA was completely converted into the two-chain 
form in 2 h, in parallel with the generation of its 
amidolytic activity (fig. 2A and 3). This conversion 
was also completely inhibited by a complex of anti- 
thrombin III/ heparin and anti-human factor Xa, 
but not by hirudin, SBTI or LBTI. These results 
exclude a possible activation by contaminating en- 
zyme in the factor Xa preparation. CaCb at 2 mM 
slightly stimulated the activating activity of factor 
Xa (fig. ll3), but phospholipid had no effect even 
in the presence of CaC12. After a 2 h incubation 
period, a small amount of t-PA amidolytic activity 
was obtained by plasma kallikrein. The ability of 
other coagulation factors including thrombin, fac- 
tor VIIa, factor IXa, factor XIa, factor XIIa and 
activated protein C to activate t-PA was negligible, 
even in the presence of their cofactors (table 2). 
4. DISCUSSION 
The experiments presented here demonstrate that 
factor Xa readily converts single-chain t-PA to its 
two-chain form with a concomitant increase in 
t-PA amidolytic activity. Other activated coagula- 
tion factors including thrombin, factor VIIa, fac- 
tor IXa, factor XIa, factor XIIa and activated pro- 
tein C failed to activate t-PA. The efficiency of 
t-PA activation by factor Xa was similar to that 
observed for plasmin and tissue kallikrein. The ac- 
tivation of t-PA by factor Xa was not appreciably 
affected by the presence of either phospholipid, 
CaCl2 or both. This represents the first known in- 
stance where factor Xa proteolysis is unaffected by 
these cofactors. Whether the activation of t-PA by 
factor Xa is a physiologically meaningful reaction 
remains to be determined. 
Like t-PA, tissue kallikrein is distributed in 
various tissues. A trace amount of tissue kallikrein 
is also present in plasma 1281. The best known 
function of tissue kallikrein is the generation of the 
vasodilator peptide, kallidin, from low-molecular- 
mass kininogen or HMW-kininogen. The present 
study reveals that the activation of t-PA is another 
possible biological function of this protease. 
The t-PA preparations isolated from uterus [5], 
heart [7] and melanoma cells [4] in the absence of 
aprotinin are principally in the two-chain form. 
Thus, it was of interest to identify and isolate the 
aprotinin-sensitive protease present in the culture 
medium responsible for the conversion of single- 
chain t-PA to the two-chain form. We have 
isolated a tissue kallikrein-like enzyme from the 
culture medium that converts single-chain t-PA to 
its two-chain form in the test tube. The inhibitor 
sensitivity and substrate specificity of the 
melanoma tissue kallikrein were identical to that 
observed for the pancreatic kallikrein used here to 
activate t-PA. Thus, it is reasonable to conclude 
that the tissue kallikrein isolated from the medium 
of melanoma cells represents a major, if not sole, 
activator of single-chain t-PA secreted by the 
melanoma cells. 
Although protease inhibitors are added during 
the purification procedures, single-chain t-PA free 
of the two-chain form has not been obtained from 
the culture of melanoma cells. Authors in [29] and 
[30] reported that a portion of the amidolytic ac- 
tivity or plasminogen-activating activity found in 
their single-chain preparation was due to the in- 
trinsic enzyme activity of single-chain form. 
Recently, controversial results were reported in 
[31] that the entire amidolytic or plasminogen ac- 
tivating activity of the single-chain t-PA prepara- 
tion was accounted for by the contaminating two- 
chain form. 
The results presented in fig. 3 are similar to [31] 
and show that the enzyme activity due to the 
single-chain form in our starting material is cer- 
tainly lower than the lo-12vo that was obtained by 
amidolytic activity. This indicates that our single- 
chain preparation was contaminated by the two- 
chain form and this two-chain form contributes to 
most enzyme activity in the starting materials. This 
contamination of two-chain form was detected on 
the gels by sensitive silver staining (fig.2). Thus, 
the increase of enzyme activity of single-chain 
t-PA during the activation could be considerably 
greater than 7- to IO-fold described here. If the 
single-chain has no enzyme activity, as claimed in 
[31], an activation of t-PA by an enzyme such as 
tissue kallikrein or factor Xa is necessary for the 
initiation of fibrinolysis. 
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